Montenovo Martin, Rahnemai-Azar Amir, Reyes Jorge, Perkins James
From the Department of Surgery, Division of Transplantation, University of Washington, Seattle, Washington, USA.
Exp Clin Transplant. 2018 Apr;16(2):166-171. doi: 10.6002/ect.2016.0277. Epub 2017 Jun 16.
The effect of portal vein thrombosis on the progression of liver disease is controversial, with no consensus on optimal treatment. We aimed to assess how portal vein thrombosis affects wait list outcomes, identify risk factors associated with its development while on a wait list, and assess its effects on patient and graft survival.
This US-based retrospective cohort study analyzed 134 109 adult patients on wait lists for or undergoing primary orthotopic liver transplant between January 2002 and June 2014. Rate of portal vein thrombosis development, time from entry on wait list to transplant, comparisons of wait list drop-off rates between patients with versus those without portal vein thrombosis, risk factors associated with its development while on a wait list, and its effects on patient and graft survival were analyzed.
We found that the rate of portal vein thrombosis at listing increased. Patients with the disease at listing were more likely to be removed from wait lists because of being too sick. Portal vein thrombosis at listing was an independent risk factor for being removed from a wait list. Of 63 265 patients who underwent primary orthotopic liver transplant, those with the disease were more likely to have higher Model for End-Stage Liver Disease scores and incidence of nonalcoholic steatohepatitis and diabetes mellitus. Portal vein thrombosis had a negative effect on patient and graft survival. Nonalcoholic steatohepatitis, body mass index, diabetes, and hepatocellular carcinoma were identified as risk factors for its development.
Portal vein thrombosis represents an increasing management and outcome burden in liver transplant. Having this disease at listing and/or at time of transplant is associated with worse patient and graft survival. Nonalcoholic steatohepatitis and hepatocellular carcinoma are among the biggest risk factors for its development while on a wait list.
门静脉血栓形成对肝病进展的影响存在争议,对于最佳治疗方法尚无共识。我们旨在评估门静脉血栓形成如何影响等待名单结果,确定在等待名单上与其发生相关的风险因素,并评估其对患者和移植物存活的影响。
这项基于美国的回顾性队列研究分析了2002年1月至2014年6月期间在等待名单上或正在接受初次原位肝移植的134109例成年患者。分析了门静脉血栓形成的发生率、从进入等待名单到移植的时间、有门静脉血栓形成的患者与无门静脉血栓形成的患者在等待名单上退出率的比较、在等待名单上与其发生相关的风险因素以及其对患者和移植物存活的影响。
我们发现登记时门静脉血栓形成的发生率有所增加。登记时患有该疾病的患者因病情过重而更有可能被从等待名单上移除。登记时的门静脉血栓形成是被从等待名单上移除的独立危险因素。在63265例接受初次原位肝移植的患者中,患有该疾病的患者更有可能具有更高的终末期肝病模型评分以及非酒精性脂肪性肝炎和糖尿病的发生率。门静脉血栓形成对患者和移植物存活有负面影响。非酒精性脂肪性肝炎、体重指数、糖尿病和肝细胞癌被确定为其发生的风险因素。
门静脉血栓形成在肝移植中代表着日益增加的管理和结果负担。在登记时和/或移植时患有这种疾病与更差的患者和移植物存活相关。非酒精性脂肪性肝炎和肝细胞癌是在等待名单上其发生的最大风险因素之一。